Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gene Logic in drug development deal with Roche
The agreement provides for Gene Logic to receive success-based milestone payments for each drug candidate Roche returns to clinical development. In addition, Gene Logic will receive royalties for
The agreement provides for Gene Logic to receive success-based milestone payments for each drug candidate Roche returns to clinical development. In addition, Gene Logic will receive royalties for
AstraZeneca will make an initial payment of GBP16.3 million and will make a GBP7.5 million equity investment in Protherics to be paid in cash. Protherics will receive additional
The company’s will initially use Ambrx’ proprietary technology platform to generate novel pegylated interferon alpha molecules. Under the terms of the agreement, Roche will fund R&D of the
K252a is a research compound being evaluated by the company’s for its potential to topically treat psoriasis, and for potential use in the prevention and treatment of restenosis.
New River said that the application had been completed on schedule and that it anticipates approval and subsequent launch for the drug in 2006. In addition, the company
Depakote extended release tablets offers patients the convenience of taking this medication once a day. When taken once-a-day, the extended release formulation of the drug helps provide more
The compound is presently in phase I development for the treatment of acute heart failure, and data emerging from this trial has encouraged the company to initiate development
NeoStem operates a commercial autologous adult stem cell bank and is pioneering the pre-disease collection, processing and storage of adult stem cells for present and future medical treatment.
In September 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a
Novartis will continue to use the Xenogen software and patented methods of biophotonic imaging for use with Xenogen’s biophotonic imaging systems. The technology will be used for research